Interim report, May–July 2020/21

Showing resilience

The world is still impacted by the Covid-19 pandemic, our industry included. But Elekta’s solid performance with positive order growth and increased profitability during the first quarter is a clear sign of our resilience and the strong underlying demand for our products. Elekta has a vital role to play for precision radiation medicine solutions – now in this time of transition and in a future situation when life will be normalized in our markets. We act forcefully to mitigate the short-term effects of the pandemic and continue to invest in innovation for long-term competitiveness.
 

Gustaf Salford
Acting President and CEO

First quarter

• Covid-19 continued to have a negative effect on Elekta’s business

• Gross order intake amounted to SEK 4,451 M (4,390), corresponding to a 4 percent growth in constant currency

• Net sales were SEK 2,981 M (3,228), corresponding to a 5 percent decrease in constant currency

• Gross margin amounted to 45.9 (42.6) percent

• EBITA increased by 23 percent to SEK 551 M (448), corresponding to an EBITA margin of 18.5 percent (13.9)

• Earnings per share was SEK 0.57 (0.38) before/after dilution

• Cash flow after continuous investments improved by SEK 810 M to SEK 26 M (-784)

• At today’s AGM the Board of Directors proposes a dividend of SEK 0.90 (1.80) per share for the fiscal year 2019/20. The Board of Directors may call for an Extraordinary General Meeting to propose an additional dividend. This is dependent on the general economic outlook and how Covid-19 will affect Elekta and its markets going forward.

No significant events after the quarter

¹ After continuous investments
² Before / after dilution
³ Based on constant currency
⁴ Compared to last rolling twelve months period Aug 2018 – Jul 2019 based on constant currency 

# # #

For further information, please contact:
Cecilia Ketels
Head of Investor Relations
Elekta AB (publ)
+46 76 611 76 25
cecilia.ketels@elekta.com

Johan Adebäck
Acting CFO 
Elekta AB (publ)
+46 70 873 33 21
johan.adeback@elekta.com

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on August 26, 2020. (REGMAR)
 

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.